The CareStart COVID-19 Antigen test kit allows for the rapid screening of COVID-19 infection on a large scale, with results in just 10 minutes. The CareStart COVID-19 Antigen Test is a lateral flow immunochromatographic assay for the detection of extracted nucleocapsid protein antigens specific to SARS-CoV-2 in swab specimens directly collected from individuals who are suspected of COVID-19 by their healthcare providers. This product is CLIA waived under FDA/EUA authorization.
Quantity: 8 Million test kits
MOQ: 1 Million
FOB: New Jersey USA
Price: 11.75 USD
The COVID-19 IgG/IgM (Whole Blood/Serum/Plasma) Rapid Test Device utilizes lateral flow technology that is used for the qualitative, differential detection of both anti-SARS-CoV-2 IgM and IgG antibodies. In general, antibodies can be detected 1-3 weeks after infection. This test is intended to screen patients for COVID-19. Combining RNA and Antibody tests can significantly raise the sensitivity for detecting COVID-19 in infected individuals.
This test has been authorized by the FDA under a EUA for professional use CLIA and CLIA WAIVED for Point Of Care.
This test has been authorized only for the presence of IgM and IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens.
This product is intended for professional use and not for home use.
FACT SHEET FOR HEALTHCARE PROVIDERS
This test has been authorized by the FDA under a EUA for use by authorized CLIA laboratories. This device is CLIA waived for point of care use for fingerstick whole blood specimens only. The user should be trained in the procedure. Wear appropriate protective attire for your safety when handling patient samples.
This test has been authorized only for the presence of IgM and IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens.
There should be a blue line in the control region (next to ) before testing, discard the device if there is no blue line.
Health Canada Authorised Rapid Test
The COVID-19 antigen rapid test device is a lateral flow in-vitro immunoassay intended to be used for the qualitative detection of the SARS-CoV-2 viral nucleoprotein. This device will detect both viable and nonviable virus in both nasopharyngeal and oropharyngeal secretions.
This test had been authorized for point of care use by Health Canada and is available for immediate dispatch
MediGuard Systems of Canada is an Authorised distributor of the Assuretech Rapid Antigen test.
Support documentation and details available on request
Product Name:
Surplex(R)-COVID-19 IgM/IgG Rapid test
Product Description:
Surplex(R)-COVID-19 IgM/IgG Rapid test is a serology test intended for the qualitative detection of IgM and IgG antibodies of the novel coronavirus (the SARS-COV-2 virus) in human serum, plasma or whole blood. It is CE marked and approved in Brazil (ANVISA approved).
We are motivated to aggressively price our product and ready to send 20 tests (one box) to qualified buyers for evaluation, free of charge.
Price of product:
FOB USD $1.50 - $2.50 per test, volume dependent.
Product origin :
China.
Key Specifications/Special Features :
- Competitively priced and ready to ship in volume.
- Currently shipping in volume to Brazil.
- Highly accurate and specific - performance independently confirmed.
- Results ready in 15 minutes.
- Harmonization System (HS) Code: 382200.
- We provide a full support during regulatory application.
Minimum Order Size and Packaging details:
MOQ: Flexible.
Box of 20 or 50 test kits.
Storage: 2-30C.
Shelf Life: 10 months.
Intended Use:
This product is authorized and intended for use by trained laboratory or healthcare professionals for in vitro diagnostic use. Point-of-care professionals administering tests are required to report all results to the appropriate public health authorities.
Note: Consult your provincial and local health care authorities for POC guidelines for rapid testing use.
310 Grooming Kits Suppliers
Short on time? Let Grooming Kits sellers contact you.